Skip to main content

The independent medical news service

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

19-12-2022 | Oncology | News | Article

Obesity may increase irAE risk among nivolumab-treated patients

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.

Radiation therapy

30-11-2022 | Oncology | News | Article

Long-term findings support SABR for localized RCC

Stereotactic ablative body radiotherapy has high local efficacy and minimal impact on renal function in the long term among people with localized renal cell carcinoma, say researchers who conducted an individual patient data meta-analysis of the IROCK database.

Syringe, vials and pills

14-11-2022 | Oncology | News | Article

Second-line metastatic RCC outcomes similar regardless of first-line immunotherapy combo partner

Among patients with metastatic clear cell renal cell carcinoma, the outcomes of second-line treatment are similar irrespective of whether they received dual immunotherapy or IO plus a tyrosine kinase inhibitor in the first line, indicates a chart review.

Close up of young woman scratching the itch on her arm - skin irritation concept.

18-10-2022 | Oncology | News | Article

Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.

23-09-2022 | Oncology | News | Article

Advanced RCC PFS boost with addition of cabozantinib to first-line dual immunotherapy

People with intermediate- or poor-risk advanced renal cell carcinoma derive a significant progression-free survival benefit from the addition of cabozantinib to first-line nivolumab plus ipilimumab, indicates the COSMIC-313 trial.